Cargando…

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib

Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonia, Chiging, Devi, Th.Gomti, Karlo, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395141/
https://www.ncbi.nlm.nih.gov/pubmed/36032699
http://dx.doi.org/10.1016/j.matpr.2022.04.868
_version_ 1784771624475557888
author Sonia, Chiging
Devi, Th.Gomti
Karlo, T.
author_facet Sonia, Chiging
Devi, Th.Gomti
Karlo, T.
author_sort Sonia, Chiging
collection PubMed
description Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and chemical properties of this molecule. The molecule is optimized by using density functional theory (DFT) method. The DFT calculations are performed using Gaussian 09 W software package. The bond lengths and bond angles between atoms in the molecules are investigated. The intramolecular interaction within the molecule is identified using the natural bond orbital (NBO) study. The atom in molecule (AIM) study is performed using Multiwfn software. All the calculations are performed at B3LYP /6311G++ (d, p) level of theory. The molecular parameters, such as first-order hyperpolarizability, HOMO-LUMO energy gap, global electrophilicity index, dipole moment, chemical potential, hardness, ionization energy and electron affinity are determined from the calculation. The molecular docking analysis of Baricitinib is also carried out against different target proteins such as 6VSB, 6W9C and 6LU7.
format Online
Article
Text
id pubmed-9395141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93951412022-08-23 DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib Sonia, Chiging Devi, Th.Gomti Karlo, T. Mater Today Proc Article Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and chemical properties of this molecule. The molecule is optimized by using density functional theory (DFT) method. The DFT calculations are performed using Gaussian 09 W software package. The bond lengths and bond angles between atoms in the molecules are investigated. The intramolecular interaction within the molecule is identified using the natural bond orbital (NBO) study. The atom in molecule (AIM) study is performed using Multiwfn software. All the calculations are performed at B3LYP /6311G++ (d, p) level of theory. The molecular parameters, such as first-order hyperpolarizability, HOMO-LUMO energy gap, global electrophilicity index, dipole moment, chemical potential, hardness, ionization energy and electron affinity are determined from the calculation. The molecular docking analysis of Baricitinib is also carried out against different target proteins such as 6VSB, 6W9C and 6LU7. Elsevier Ltd. 2022 2022-05-11 /pmc/articles/PMC9395141/ /pubmed/36032699 http://dx.doi.org/10.1016/j.matpr.2022.04.868 Text en Copyright © 2022 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the XII th Biennial National Conference of Physics Academy of North East (PANE 2021). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sonia, Chiging
Devi, Th.Gomti
Karlo, T.
DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title_full DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title_fullStr DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title_full_unstemmed DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title_short DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
title_sort dft study on the structural and chemical properties of janus kinase inhibitor drug baricitinib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395141/
https://www.ncbi.nlm.nih.gov/pubmed/36032699
http://dx.doi.org/10.1016/j.matpr.2022.04.868
work_keys_str_mv AT soniachiging dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib
AT devithgomti dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib
AT karlot dftstudyonthestructuralandchemicalpropertiesofjanuskinaseinhibitordrugbaricitinib